Daniella Spittle

Ms. Daniella Spittle


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
MAMichael N. Armitage
Michael N. Armitage
DSDaniella Spittle
Daniella Spittle
Alice M TurnerAlice M Turner
Alice M Turner
Background: Half of acute exacerbations of COPD are due to bacterial infection, and the other half are likely influenced by microbial colonisation. The same organisms commonly cultured during acute exacerbations are often found in the sputum of patients during stability. A robust assessment of the prevalence of potentially pathogenic microorganisms (PPMs) in the sputum of stable COPD patients may help to inform the targeted prevention of exacerbation by these organisms. Methods: A systematic review and meta-analysis was carried out to determine the prevalence of PPMs in patients with COPD in the stable state. Meta-analysis of prevalence was carried out using the Freeman–Tukey double arcsine transformation random effects model, and sub-group analysis was performed for sputum modality. Prevalence of total and individual PPMs was calculated from patient-level data from individual studies. Results: Pooled prevalence of PPMs identified by sputum culture was found to be 41% (95% CI 36–47%). Significant heterogeneity was found across all studies, which can likely be attributed to inconsistent measuring and reporting of PPMs. The most commonly reported organisms were H. influenzae, M catarrhalis, S. pneumoniae, S. aureus, and P. aeruginosa. Declining lung function was weakly correlated with prevalence of PPMs. Conclusion: The airways of patients with COPD are colonised with PPMs during the stable state in almost half of patients. A complex relationship likely exists between the microbiome in the stable state and the phenotype of COPD patients. Targeted microbial therapy for preventing exacerbations of COPD should carefully consider the stable microbiome as well as the exacerbated.

15 July 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
DSDaniella Spittle
Daniella Spittle
AMAlison Mansfield
Alison Mansfield
APAnita Pye
Anita Pye
Alice M TurnerAlice M Turner
Alice M Turner
MNMichael Newnham
Michael Newnham
Lung disease progression in alpha-1 antitrypsin deficiency (AATD) is heterogenous and manifests in different ways. Blood biomarkers are an attractive method of monitoring diseases as they are easy to obtain and repeatable. In non-AATD COPD, blood biomarker panels have predicted disease severity, progression, and mortality. We measured a panel of seven serum biomarkers in 200 AATD patients and compared levels between those with COPD and those without. We assessed whether biomarkers were associated with baseline lung function parameters (FEV1 and TLco) or absolute change in these parameters. In total, 111 patients with a severely deficient genotype of AATD (PiZZ) and COPD were included in the analyses. Pearson’s correlation coefficient was measured for biomarker correlations and models were compared using ANOVA. CRP and CCL18 were significantly higher in the serum of AATD COPD versus AATD with no COPD. Biomarkers were not predictive of cross-sectional lung function measurements, however, CC16 was significantly associated with an absolute change in TLco (p = 0.018). An addition of biomarkers to the predictive model for TLco added significant value over covariates alone (R2 0.13 vs. 0.02, p = 0.028). Our findings suggest that CC16 is predictive of emphysema progression in AATD COPD. Proteomics data may reveal alternative candidate biomarkers and further work should include the use of longitudinal biomarker measurements.

27 June 2024 in ERJ Open Research
Verified
Journal Article
Open access
PDF file
DSDaniella Spittle
Daniella Spittle
MTMaximillian Thomas
Maximillian Thomas
CSCaitlin Stevens
Caitlin Stevens
AGAbdulrhman Gazwani
Abdulrhman Gazwani
SFSally Fenton
Sally Fenton
Alice M TurnerAlice M Turner
Alice M Turner
Background: Dysfunction of the small airways is a precursor of COPD but is not detectable on standard spirometric testing until significant destruction has occurred. A proportion of COPD patients have a forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) <0.7 which is greater than the lower limit of normal (LLN), when adjusted for their age and sex. It is not understood whether this group of patients, known as “discordant COPD”, are representative of “early COPD” or overdiagnosis.Methods: We sought to characterise discordant COPD (disCOPD) using radiology, lung function, serum biomarkers, activity monitoring and quality-of-life scores, comparing with COPD patients with an FEV1/FVC <0.7 and <LLN and healthy, age-matched controls.Results: Six out of eight serum biomarkers were significantly different in the disCOPD groupversushealthy controls, as were the scores of all four quality-of-life questionnaires. Activity monitoring revealed similar levels of sedentary time between the disCOPD group and concordant COPD (conCOPD). Computed tomography analysis showed less involvement of small airway dysfunction and emphysema in the disCOPD groupversusconCOPD.Conclusions: Collectively, our findings support the hypothesis that disCOPD is a clinically relevant phenomenon that represents a pre-COPD state. Identification of such patients is important for early intervention and management before progression to fully established COPD.

19 March 2026
Verified
Conference Paper
Closed access
DSDaniella Spittle
Daniella Spittle
JSJoshua De Soyza
Joshua De Soyza
APAnita Pye
Anita Pye
ATAlice Turner
Alice Turner
Despite being a genetic risk factor, not all patients with alpha-1 antitrypsin deficiency (AATD) develop COPD. Moreover, disease progression varies in AATD, yet the molecular mechanisms driving this heterogeneity remain unclear. This study investigated protein-level differences that may contribute to disease pathophysiology in severe AATD. Serum samples from participants in the Alpha-1 Registry were analysed using the SomaScan® 7k assay (SomaLogic). The analysis included only those with the PiZZ genotype—the variant linked to the most profound deficiency—and excluded participants with bronchiectasis. Comparative proteomic profiling was conducted between 98 participants diagnosed with COPD and 51 without COPD. Differential expression was summarised using log₂ fold change and adjusted p-values (false discovery rate). Proteins most elevated in AATD-COPD included AGER, CILP2, IGDCC4, IGFALS, and tetranectin, while the most reduced were PLAT, cathepsin D, TAGLN, LILRA5, and complement C7. These patterns suggest roles in persistent inflammation (AGER), extracellular matrix remodelling (CILP2, tetranectin), and immune regulation (LILRA5, C7). Reduced PLAT and cathepsin D imply defects in fibrinolytic and lysosomal pathways, potentially impairing tissue repair and immune defence. Elevated AGER further supports oxidative and epithelial stress mechanisms contributing to COPD pathobiology in AATD. In summary, AATD individuals with COPD display a distinct serum proteomic profile implicating disrupted fibrinolytic balance, immune dysregulation, and inflammatory signalling. These findings may inform biomarker discovery and targeted therapies.